MedTrace Logo

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT07096778 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Conditions

  • Multiple Myeloma Refractory
  • Multiple Myeloma in Relapse

Interventions

DRUG

Inobrodib

20 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.

DRUG

Pomalidomide

4 mg orally once daily on Day 1 to 21 of each 28-day cycle

DRUG

Dexamethasone

40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle

Sponsors & Collaborators

  • CellCentric Ltd.

    lead INDUSTRY

Principal Investigators

  • Naseer Qayum · CellCentric Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2029-12-01
Completion
2029-12-01
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07096778 on ClinicalTrials.gov